Free Trial
NASDAQ:FBLG

FibroBiologics Q1 2024 Earnings Report

FibroBiologics logo
$0.88 -0.02 (-2.54%)
As of 10:07 AM Eastern

FibroBiologics EPS Results

Actual EPS
-$0.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
5:25PM ET

Upcoming Earnings

FibroBiologics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 5:25 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

FibroBiologics Earnings Headlines

FibroBiologics Presenting at the ThymUS 2025 Meeting
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
FibroBiologics announces opening of new lab facility
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG) operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile

More Earnings Resources from MarketBeat